No Data
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
Biogen's Felzartamab: A Potential Blockbuster in Kidney Treatment With Unique Anti-CD38 Approach
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
102124711 : .
Optanie Numa Marc : PLTR is my prediction.
Salini : PLTR
72377867 Jaddy : NDAQ
105251507 : plntr will add..maybe 1 bitcoin company like microstrategy
View more comments...